Loading clinical trials...
Loading clinical trials...
A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF CE-224,535, AN ANTAGONIST OF THE P2X7 RECEPTOR, IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN SUBJECTS WHO ARE INADEQUATELY CONTROLLED ON METHOTREXATE
Conditions
Interventions
CE-224,535
Placebo
Locations
27
United States
Arizona Arthritis & Rheumatology Associates, P.C.
Mesa, Arizona, United States
Omega Research Consultants LLC
DeBary, Florida, United States
Florida Arthritis Center
Lake Mary, Florida, United States
Tampa Medical Group, PA
Tampa, Florida, United States
American Health Network
Avon, Indiana, United States
Best Clinical Trials, LLC (Administrative Only)
New Orleans, Louisiana, United States
Start Date
April 7, 2008
Primary Completion Date
February 4, 2009
Completion Date
February 4, 2009
Last Updated
April 4, 2022
NCT05961592
NCT07017686
NCT05038553
NCT05790356
NCT05657847
NCT03429426
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions